A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval ... them a Novartis drug recently awarded accelerated approval.

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

Travere Therapeutics TVTX announced that the FDA ... approval to its oral non-immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.

On Friday, the U.S. Food and Drug Administration approved ... progression of eczema. The FDA's approval is a "big win for ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

The submission, made on Tuesday, aims to secure approval for OLC's use in treating hyperphosphatemia in patients with chronic kidney disease ... for the drug's potential launch. The FDA has ...

LOS ALTOS, Calif. - Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...